What does this score mean?
The Confidence Index is an editorial methodology score that indicates the degree to which the scientific finding evaluated on this page can be trusted, not the success rate of the treatment. Study design, risk of bias, sample size, precision, direct applicability, reproducibility, transparency, and clinical relevance are evaluated together.
What did the study investigate?
It evaluated whether the benefits and risks reported in adult human studies regarding psilocybin microdosing are supported by controlled data.
How was it conducted?
Using the PRISMA approach, data from 11 studies and 3,262 adults were systematically reviewed; due to study heterogeneity, a meta-analysis could not be performed.
What was found?
Positive experiences were reported in observational and self-report studies; however, significant clinical benefit was largely not confirmed in placebo-controlled studies.
Limitations of the study
Studies are heterogeneous in terms of dose, product, follow-up, and outcome measures; the expectancy effect is strong, and adverse event reporting is inadequate.
What does this mean clinically?
Current evidence does not support microdosing as an established clinical or biohacking protocol; full-dose psilocybin data from regulated research settings should not be generalized to microdosing.
What do we not know yet?
Long-term safety, true pharmacological effect size, standardized dosing, and which groups might benefit remain uncertain.
Source
The full citation and links of the sources are preserved in the detailed evaluation section of this page.
Written and medically reviewed by: Dr. Kerem Çağlayan · All Scientific Research
Detailed evaluation
Research evaluation · September 12, 2026
A PRISMA systematic review published in Frontiers in Psychiatry on August 19, 2026, compiled adult human data regarding the microdose use of psilocybin-containing mushrooms or truffles. A total of 11 studies and 3,262 adults were evaluated.
What did the systematic review examine?
Five quantitative and six qualitative studies were included in the review. The studies were conducted in different countries and demonstrated marked heterogeneity in terms of the product used, dosage, dosing frequency, outcome measures, and follow-up duration. Due to this heterogeneity, a meta-analysis could not be performed.
A significant portion of participants used microdosing not for a medical diagnosis, but for reasons such as well-being, creativity, focus, or personal growth. While this reflects real-world experience, it makes drawing causal conclusions about clinical efficacy difficult.
What were the positive reports?
In some observational and qualitative studies, positive changes in mood, mental well-being, specific areas of cognitive performance, creativity, relationships, pain, and sensory experiences were reported. However, most of these studies relied on self-reports and could not rule out the placebo/expectancy effect.
The fact that microdosing creates strong expectations in popular culture is particularly important. If an individual knows what they are taking, the expectation of change itself can influence evaluations of mood and performance.
What did controlled studies show?
The two placebo-controlled studies in the review showed no significant clinical improvement in most of the examined health outcomes. Therefore, it is unclear how much of the observationally reported benefits stems from a true pharmacological effect versus expectations, selection bias, or concurrent behavioral changes.
Is the mechanism theoretically plausible?
Psilocybin is converted into psilocin in the body and affects serotonergic signaling, particularly via 5-HT2A receptors. In controlled psychotherapy studies conducted with full-dose psilocybin, there is strong research interest regarding neuroplasticity and brain network dynamics. However, it has not been demonstrated that the subperceptual dose intended in microdosing produces the same biological effect in sufficient magnitude.
Therefore, directly extrapolating findings from full-dose, supervised psilocybin research to microdosing is not scientifically valid.
What do we know about safety?
One of the most significant limitations of the review is the inadequate reporting of adverse events. Although the reported issues were mostly mild, clinically significant events such as anxiety, panic, confusion, and psychotic symptoms have been reported.
Risk assessment is far more critical particularly in the presence of bipolar disorder, a history of psychotic disorders, active suicide risk, uncontrolled cardiovascular disease, and pregnancy. In addition, self-discontinuation or uncontrolled concurrent use of serotonergic medications or MAOIs should not be considered safe.
Is there sufficient data to establish a “microdose protocol”?
No. The mushroom species, psilocybin content, doses, and administration schedules used in the studies varied substantially. The review cannot identify a reproducible “effective microdose” or a safe long-term schedule.
Impact on practice
Does not change practice. Based on current data, psilocybin microdosing should not be recommended as a clinical or biohacking protocol. Findings from full-dose psilocybin studies conducted in regulated research settings should not be conflated with uncontrolled community microdosing.
Quality of evidence
Low. Although the methodology of the systematic review is robust, most of the included studies are observational, qualitative, or carry a high/unclear risk of bias. The fact that two placebo-controlled studies were negative warrants a more cautious interpretation of positive self-reports.
Reference
Page J, Moore A, Hawkins BE, Lyons EJ, Lorenzo E. The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing. Frontiers in Psychiatry. 2026;17:1866881.
Image: scientific visual showing brain network communication after psilocybin; Petri et al./Wikimedia Commons, CC BY-SA 4.0. This visual is not specific to the microdose study; it is used to represent the brain network effects of psilocybin.